Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D et al.
Journal of Chemical Information and Modeling, 2024
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus.
Charnaud S et al.
Communications Biology, 2022
The Identification of Novel CYP2D6 Variants in US Hmong: Results From Genome Sequencing and Clinical Genotyping.
Wen YF et al.
Frontiers in Pharmacology, 2022
Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2021
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data.
van der Lee M et al.
Science Translational Medicine, 2021
Spontaneous Ligand Access Events to Membrane-Bound Cytochrome P450 2D6 Sampled at Atomic Resolution.
Fischer A et al.
Scientific Reports, 2019
Molecular Dynamics Simulations Reveal Structural Differences among Allelic Variants of Membrane-Anchored Cytochrome P450 2D6.
Fischer A et al.
Journal of Chemical Information and Modeling, 2018
CYP2D6 Allelic Variants *34, *17-2, *17-3, and *53 and a Thr309Ala Mutant Display Altered Kinetics and NADPH Coupling in Metabolism of Bufuralol and Dextromethorphan and Altered Susceptibility to Inactivation by SCH 66712.
Glass SM et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2018
Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function.
Don CG et al.
Plos One, 2018
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
Molecular dynamics of CYP2D6 polymorphisms in the absence and presence of a mechanism-based inactivator reveals changes in local flexibility and dominant substrate access channels.
de Waal PW et al.
Plos One, 2014
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clinical Pharmacokinetics, 2009
Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008